Correlation between plasma concentration ratios of SN-38 glucuronide and sn-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene

Oncology Letters

Volumn 3, Issue 3, 2012, Pages 694-698

  Hirose, Koichi ^a   Kozu, Chihiro ^a   Yamashita, Koshiro ^a   Maruo, Eiji ^a   Kitamura, Mizuho ^a   Hasegawa, Junichi ^a   Omoda, Kei ^a   Murakami, Teruo ^b   Maeda, Yorinobu ^a  

^a OSAKA ROSAI HOSPITAL   (Japan)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

FOLFILI regimen; Irinotecan hydrochloride; Neutropenia; Plasma SN 38G SN 38 ratio; Polymorphism of UGT1A1; UDP glucuronosyltransferase

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTINUOUS INFUSION; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME METABOLISM; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEUTROPENIA; NEUTROPHIL; UREA NITROGEN BLOOD LEVEL;

EID: 84855668889     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.533     Document Type: Article

References (22)

1. Shimoyama S: Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events. World J Gastrointest Surg 2: 14-21, 2010.
2. Hasegawa Y, Ando Y and Shimokata K: Screening for adverse reactions to irinotecan treatment using the invader UGT1A1 molecular assay. Expert Rev Mol Diagn 6: 527-533, 2006.
3. Ratain MJ and Innocenti F: Individualizing dosing of irinotecan. Clin Cancer Res 16: 371-372, 2010.
4. Glimelius B, Garmo H, Berglund A, et al: Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 11: 61-71, 2011.
5. Chabot GG, Abigerges D, Catimel G, et al: Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6: 141-151, 1995.
6. Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33: 245-259, 1997.
7. Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60: 6921-6926, 2000.
8. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutopenia of irinotecan. J Clin Oncol 22: 1382-1388, 2004.
9. Araki K, Fujita K, Ando Y, et al: Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97: 1255-1259, 2006.
10. Minami H, Sai K, Saeki M, et al: Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17: 497-504, 2007.
11. Sai K, Sawada J and Minami H: Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1*6 and *28. Yakugaku Zasshi 128: 575-584, 2008.
12. Mathijssen RH, van Alphen RJ, Verweij J, et al: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7: 2182-2194, 2001.
13. Koo DH, Lee JL, Kim TW, et al: A phase II study of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. J Korean Med Sci 22: 98-103, 2007.
14. Kurita A and Kaneda N: High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. J Chromatogr B 724: 335-344, 1999.
15. Itoh T, Takemoto I, Hata Y, et al: Determination of the lactone forms and carboxylate forms of irinotecan and its active metabolite, glucuronide by high-performance liquid chromatography. Jpn J Ther Drug Monit 17: 383-389, 2000.
16. Takane H, Miyata M, Burioka N, et al: Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit 29: 666-668, 2007.
17. Nozawa T, Minami H, Sugiura S, Tsuji A and Tamai I: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33: 434-439, 2005.
18. Tanaka H, Saito K, Mino K, et al: Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity. Jpn J Cancer Chemother 36: 1505-1509, 2009.
19. Onoue M, Terada T, Kobayashi M, et al: UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 14: 136-142, 2009.
20. Oostendorp RL, van de Steeg E, van der Kruijssen CM, et al: Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos 37: 917-923, 2009.
21. Marsh S and Hoskins JM: Irinotecan pharmacogenomics. Pharmacogenomics 11: 1003-1010, 2010.
22. Sai K, Saito Y, Maekawa K, et al: Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol 66: 95-105, 2010.